What Is Tirzepatide?
Tirzepatide is a synthetic 39-amino acid peptide that simultaneously activates both GIP and GLP-1 receptors, the two key incretin hormones regulating postprandial insulin secretion, appetite, and energy balance. This dual mechanism distinguishes it from earlier GLP-1 receptor agonists such as semaglutide and liraglutide, which target only the GLP-1 receptor.
Developed by Eli Lilly under the brand names Mounjaro (diabetes) and Zepbound (weight management), tirzepatide has produced the largest weight loss results of any approved pharmacotherapy in clinical history. The SURMOUNT-1 trial demonstrated a mean weight reduction of 22.5% at the 15 mg dose over 72 weeks (trial product estimand) in non-diabetic obese adults, a result that fundamentally shifted expectations for obesity pharmacotherapy.How It Works
Dual Incretin Receptor Activation
Tirzepatide's primary mechanism involves simultaneous agonism at both GIP and GLP-1 receptors. Both receptors are expressed on pancreatic beta cells, where their activation potentiates glucose-dependent insulin secretion. The glucose-dependent nature of this mechanism means insulin release is triggered only when blood glucose is elevated, substantially minimizing hypoglycemia risk compared to traditional insulin therapy.
GIP and GLP-1 also act through partially distinct downstream pathways, providing additive or synergistic effects on glycemic control and weight reduction that exceed what GLP-1 agonism alone can achieve.Appetite Suppression
Both GIP and GLP-1 receptors are expressed in hypothalamic regions governing appetite and energy balance, particularly the arcuate nucleus and ventromedial hypothalamus. Tirzepatide's activation of both receptor populations reduces hunger signaling and increases satiety, producing the marked caloric intake reductions observed in clinical trials. This central appetite suppression is considered a primary driver of tirzepatide's superior weight loss outcomes.
Delayed Gastric Emptying
GLP-1 receptor activation slows the rate at which food exits the stomach, prolonging postprandial satiety and attenuating postmeal glucose excursions. This effect contributes to both glycemic control and reduced caloric intake by extending the subjective experience of fullness after meals.
Metabolic Effects
Beyond insulin secretion and appetite, tirzepatide appears to enhance lipid metabolism and preferentially reduce visceral adipose tissue, the metabolically active fat depot most strongly associated with cardiometabolic risk. GIP receptor activation may also enhance lipid storage efficiency in adipose tissue, contributing to improved lipid profiles observed in clinical studies.